Felsher Lab In the Division of Oncology

The Felsher Laboratory Publications

Featured Publications

1: Li Y, Choi PS, Felsher DW. Oncogene addiction: resetting the safety switch?
Oncotarget. 2014 Sep 20. [Epub ahead of print] PubMed PMID: 25275297.

2: Li Y, Choi PS, Casey SC, Felsher DW. Activation of cre recombinase alone can
induce complete tumor regression. PLoS One. 2014 Sep 10;9(9):e107589. doi:
10.1371/journal.pone.0107589. eCollection 2014. PubMed PMID: 25208064; PubMed
Central PMCID: PMC4160265.

3: Li Y, Choi PS, Casey SC, Dill DL, Felsher DW. MYC through miR-17-92 suppresses
specific target genes to maintain survival, autonomous proliferation, and a
neoplastic state. Cancer Cell. 2014 Aug 11;26(2):262-72. doi:
10.1016/j.ccr.2014.06.014. PubMed PMID: 25117713.

4: Casey SC, Li Y, Fan AC, Felsher DW. Oncogene withdrawal engages the immune
system to induce sustained cancer regression. J Immunother Cancer. 2014 Jul
15;2:24. doi: 10.1186/2051-1426-2-24. eCollection 2014. Review. PubMed PMID:
25089198; PubMed Central PMCID: PMC4118610.

5: Choi PS, Li Y, Felsher DW. Addiction to multiple oncogenes can be exploited to
prevent the emergence of therapeutic resistance. Proc Natl Acad Sci U S A. 2014
Aug 12;111(32):E3316-24. doi: 10.1073/pnas.1406123111. Epub 2014 Jul 28. PubMed
PMID: 25071175; PubMed Central PMCID: PMC4136575.

6: Eberlin LS, Gabay M, Fan AC, Gouw AM, Tibshirani RJ, Felsher DW, Zare RN.
Alteration of the lipid profile in lymphomas induced by MYC overexpression. Proc
Natl Acad Sci U S A. 2014 Jul 22;111(29):10450-5. doi: 10.1073/pnas.1409778111.
Epub 2014 Jul 3. PubMed PMID: 24994904; PubMed Central PMCID: PMC4115527.

7: Gabay M, Li Y, Felsher DW. MYC activation is a hallmark of cancer initiation
and maintenance. Cold Spring Harb Perspect Med. 2014 Jun 2;4(6). pii: a014241.
doi: 10.1101/cshperspect.a014241. PubMed PMID: 24890832.

8: Ye D, Shuhendler AJ, Cui L, Tong L, Tee SS, Tikhomirov G, Felsher DW, Rao J.
Bioorthogonal cyclization-mediated in situ self-assembly of small-molecule probes
for imaging caspase activity in vivo. Nat Chem. 2014 Jun;6(6):519-26. doi:
10.1038/nchem.1920. Epub 2014 Apr 28. PubMed PMID: 24848238; PubMed Central
PMCID: PMC4031611.

9: Casey SC, Li Y, Felsher DW. An essential role for the immune system in the
mechanism of tumor regression following targeted oncogene inactivation. Immunol
Res. 2014 May;58(2-3):282-91. doi: 10.1007/s12026-014-8503-6. PubMed PMID:

10: Li Y, Casey SC, Felsher DW. Inactivation of MYC reverses tumorigenesis. J
Intern Med. 2014 Jul;276(1):52-60. doi: 10.1111/joim.12237. Review. PubMed PMID:
24645771; PubMed Central PMCID: PMC4065197.

11: Cao Z, Ding BS, Guo P, Lee SB, Butler JM, Casey SC, Simons M, Tam W, Felsher
DW, Shido K, Rafii A, Scandura JM, Rafii S. Angiocrine factors deployed by tumor
vascular niche induce B cell lymphoma invasiveness and chemoresistance. Cancer
Cell. 2014 Mar 17;25(3):350-65. doi: 10.1016/j.ccr.2014.02.005. PubMed PMID:
24651014; PubMed Central PMCID: PMC4017921.

12: Nwabugwu CI, Rakhra K, Felsher DW, Paik DS. A tumor-immune mathematical model
of CD4+ T helper cell dependent tumor regression by oncogene inactivation. Conf
Proc IEEE Eng Med Biol Soc. 2013;2013:4529-32. doi: 10.1109/EMBC.2013.6610554.
PubMed PMID: 24110741.

13: Rakhra K, Felsher DW. Generation of a tetracycline regulated mouse model of
MYC-induced T-cell acute lymphoblastic leukemia. Methods Mol Biol.
2013;1012:221-35. doi: 10.1007/978-1-62703-429-6_15. PubMed PMID: 24006068.

14: Ansari C, Tikhomirov GA, Hong SH, Falconer RA, Loadman PM, Gill JH, Castaneda
R, Hazard FK, Tong L, Lenkov OD, Felsher DW, Rao J, Daldrup-Link HE. Development
of novel tumor-targeted theranostic nanoparticles activated by membrane-type
matrix metalloproteinases for combined cancer magnetic resonance imaging and
therapy. Small. 2014 Feb 12;10(3):566-75, 417. doi: 10.1002/smll.201301456. Epub
2013 Aug 27. PubMed PMID: 24038954; PubMed Central PMCID: PMC3946335.

15: Fan AC, O'Rourke JJ, Praharaj DR, Felsher DW. Real-time nanoscale proteomic
analysis of the novel multi-kinase pathway inhibitor rigosertib to measure the
response to treatment of cancer. Expert Opin Investig Drugs. 2013
Nov;22(11):1495-509. doi: 10.1517/13543784.2013.829453. Epub 2013 Aug 12. Review.
PubMed PMID: 23937225; PubMed Central PMCID: PMC4111569.

16: Casey SC, Bellovin DI, Felsher DW. Noncanonical roles of the immune system in
eliciting oncogene addiction. Curr Opin Immunol. 2013 Apr;25(2):246-58. doi:
10.1016/j.coi.2013.02.003. Epub 2013 Apr 6. Review. PubMed PMID: 23571026; PubMed
Central PMCID: PMC3683588.

Search PubMed for all articles


Footer Links: